• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - H2 2011 Product Image

Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - H2 2011

  • Published: November 2011
  • Region: Global
  • 69 pages
  • Global Markets Direct

Santen Pharmaceutical Co., Ltd. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - H2 2011” provides data on the Santen Pharmaceutical Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Santen Pharmaceutical Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Santen Pharmaceutical Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Santen Pharmaceutical Co., Ltd. - Brief Santen Pharmaceutical Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Santen Pharmaceutical Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across READ MORE >



List of Tables
List of Figures
Santen Pharmaceutical Co., Ltd. Snapshot
Santen Pharmaceutical Co., Ltd. Overview
Key Information
Key Facts
Santen Pharmaceutical Co., Ltd. – Research and Development Overview
Key Therapeutic Areas
Santen Pharmaceutical Co., Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Santen Pharmaceutical Co., Ltd. – Pipeline Products Glance
Santen Pharmaceutical Co., Ltd. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Santen Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Santen Pharmaceutical Co., Ltd. – Drug Profiles
DE-090
Product Description
Mechanism of Action
R&D Progress
DE-098
Product Description
Mechanism of Action
R&D Progress
DE-101
Product Description
Mechanism of Action
R&D Progress
DE-102
Product Description
Mechanism of Action
R&D Progress
DE-105
Product Description
Mechanism of Action
R&D Progress
DE-109
Product Description
Mechanism of Action
R&D Progress
DE-110
Product Description
Mechanism of Action
R&D Progress
DE-111
Product Description
Mechanism of Action
R&D Progress
DE-114
Product Description
Mechanism of Action
R&D Progress
Prolacria
Product Description
Mechanism of Action
Santen Pharmaceutical Co., Ltd. – Pipeline Analysis
Santen Pharmaceutical Co., Ltd. – Pipeline Products by Therapeutic Class
Santen Pharmaceutical Co., Ltd. - Pipeline Products By Target
Santen Pharmaceutical Co., Ltd. – Pipeline Products by Route of Administration
Santen Pharmaceutical Co., Ltd. – Pipeline Products by Molecule Type
Santen Pharmaceutical Co., Ltd. – Recent Pipeline Updates
Santen Pharmaceutical Co., Ltd. - Dormant Projects
Santen Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
DE-092
DE-099
DE-101
DE-104
DE-109
Santen Pharmaceutical Co., Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 30, 2009: MacuSight Provides Clinical Development Update For Perceiva
Oct 29, 2007: Vistakon Pharmaceuticals Introduced IQUIX (levofloxacin Ophthalmic Solution) 1.5% – A Milestone in the Treatment of Corneal Ulcers
Sep 27, 1999: Santen's Alamast received US FDA approval which is an anti-allergy eyedrops
Feb 26, 2008: MacuSight Announces Positive Preliminary Results From Phase I Study Of Sirolimus In Wet Age-Related Macular Degeneration
Oct 23, 2000: Santen Announced Quixin Anti-Infective Eye Drops Now Available.
Dec 22, 2010: Clinical Data Receives Notice Of IND Filing By Santen For ATL313
Oct 21, 2009: MacuSight Receives Fast Track Designation From FDA For Perceiva In Treatment Of Diabetic Macular Edema
Aug 21, 2000: Santen Received FDA Approval of Quixin, Anti-Infective Eye Drops.
Apr 16, 2010: Santen And Inspire Announce Approval Of DIQUAS For Treatment Of Dry Eye In Japan
Oct 15, 2004: Argenes and Santen Pharmaceuticals Sign a Licensing Agreement for the Development of Novel Anti-rheumatic Agent Anti-apo-1/Fas Monoclonal Antibody in Japan
Feb 14, 2006: Santen Announces Preliminary Results Of Overseas Clinical Trials Of Two Glaucoma Drug Candidates
Dec 13, 2010: Tibotec Receives FDA Approval For HIV-1 Drug
Sep 08, 2011: Santen Announces EMA Orphan Drug Status For Sirolimus
Apr 07, 2000: Santen Pharmaceutical Submitted New Drug Application for Quixin Antibacterial Eye Drops.
Oct 05, 2007: Argenes Initiates Phase I Clinical Study of ARG098 (Anti-fas Igm Monoclonal Antibody) for Rheumatoid Arthritis in Europe
May 05, 2000: New Data Demonstrate Value of Alamast in Treating Allergic Conjunctivitis
Oct 04, 2005: Daiichi Sankyo Licenses CS-011 To Santen
Mar 03, 2009: Santen To Launch Sante FX V Plus OTC Eye Drop In Japan
Mar 02, 2010: Santen Files Manufacturing And Marketing Approval Of DE-108 In Japan
Nov 01, 2006: MacuSight Initiates Wet Age-Related Macular Degeneration Study
Mar 01, 2004: Santen Receives FDA Approval Of Iquix, New Treatment For Sight-threatening Condition Levofloxacin 1.5% is Third Santen-Developed Product Approved in Recent Years
Financial Deals Landscape
Santen Pharmaceutical Co., Ltd., Deals Summary
Santen Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Santen Pharmaceutical Acquires Marketing Rights For RESCULA From R-Tech Ueno
Partnerships
Bausch & Lomb Enters Into Agreement With Santen Pharmaceutical
Inspire Enters Into Co-Marketing Agreement With Santen
Banyu Pharmaceutical Enters Into Co-Promotion Agreement With Santen Pharmaceutical
R-Tech Ueno Extends Co-Marketing Agreement With Santen Pharmaceutical
Santen Pharmaceutical Enters Into Co-Development Agreement With UBE Industries
CytoPathfinder Enters Into Research Agreement With Santen Pharmaceutical
Santen Pharmaceutical Enters Into Agreement With Sankyo
Santen Pharmaceutical Enters Into Co-development Agreement With Argenes
Santen Pharmaceutical Enters Into Distribution Agreement With VISTAKON Pharmaceuticals
Licensing Agreements
Clinical Data Enters Into Licensing Agreement With Santen Pharmaceutical
Merck & Co Enters Into Licensing Agreement With Santen Pharmaceutical
Santen Pharmaceutical Enters Into Licensing Agreement With MacuSight
Oakwood Laboratories Enters Into Licensing Agreement With Santen Pharmaceutical
Ono Pharmaceutical Enters Into Licensing Agreement With Santen Pharmaceutical
Equity Offering
Argenes Completes Private Placement Of $8.4 Million
Acquisition
Santen Pharmaceutical To Acquires Novagali Pharma For $69 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Santen Pharmaceutical Co., Ltd. – Pipeline by Therapy Area and Indication, H2 2011
Santen Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, H2 2011
Santen Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, H2 2011
Santen Pharmaceutical Co., Ltd. – Phase III, H2 2011
Santen Pharmaceutical Co., Ltd. - Phase II, H2 2011
Santen Pharmaceutical Co., Ltd. - Phase I, H2 2011
Santen Pharmaceutical Co., Ltd. - Pipeline By Therapeutic Class, H2 2011
Santen Pharmaceutical Co., Ltd. - Pipeline By Target, H2 2011
Santen Pharmaceutical Co., Ltd. – Pipeline By Route of Administration, H2 2011
Santen Pharmaceutical Co., Ltd. – Pipeline By Molecule Type, H2 2011
Santen Pharmaceutical Co., Ltd. – Recent Pipeline Updates, H2 2011
Santen Pharmaceutical Co., Ltd. - Dormant Developmental Projects, 2010
Santen Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2010
Santen Pharmaceutical Co., Ltd., Other Locations
Santen Pharmaceutical Co., Ltd., Subsidiaries
Santen Pharmaceutical Co., Ltd., Deals Summary
Santen Pharmaceutical Acquires Marketing Rights For RESCULA From R-Tech Ueno
Bausch & Lomb Enters Into Agreement With Santen Pharmaceutical
Inspire Enters Into Co-Marketing Agreement With Santen
Banyu Pharmaceutical Enters Into Co-Promotion Agreement With Santen Pharmaceutical
R-Tech Ueno Extends Co-Marketing Agreement With Santen Pharmaceutical
Santen Pharmaceutical Enters Into Co-Development Agreement With UBE Industries
CytoPathfinder Enters Into Research Agreement With Santen Pharmaceutical
Santen Pharmaceutical Enters Into Agreement With Sankyo
Santen Pharmaceutical Enters Into Co-development Agreement With Argenes
Santen Pharmaceutical Enters Into Distribution Agreement With VISTAKON Pharmaceuticals
Clinical Data Enters Into Licensing Agreement With Santen Pharmaceutical
Merck & Co Enters Into Licensing Agreement With Santen Pharmaceutical
Santen Pharmaceutical Enters Into Licensing Agreement With MacuSight
Oakwood Laboratories Enters Into Licensing Agreement With Santen Pharmaceutical
Ono Pharmaceutical Enters Into Licensing Agreement With Santen Pharmaceutical
Argenes Completes Private Placement Of $8.4 Million
Santen Pharmaceutical To Acquires Novagali Pharma For $69 Million

List of Figures
Santen Pharmaceutical Co., Ltd. – Pipeline by Therapy Area and Indication, H2 2011
Santen Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, H2 2011
Santen Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, H2 2011
Santen Pharmaceutical Co., Ltd. – Pipeline By Therapeutic Class, H2 2011
Santen Pharmaceutical Co., Ltd. - Pipeline By Target, H2 2011
Santen Pharmaceutical Co., Ltd. – Pipeline By Route of Administration, H2 2011
Santen Pharmaceutical Co., Ltd. – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS